Important pharmacogenetic information for drugs prescribed during the SARS-CoV-2 infection (COVID-19)
Entity
UAM. Departamento de FarmacologíaPublisher
Wiley; Society for Clinical and Translational ScienceDate
2020-09-16Citation
10.1111/cts.12866
Clinical and Translational Science (2020): 16 September
ISSN
1752-8054 (print); 1752-8062 (online)DOI
10.1111/cts.12866Funded by
M.N.-G. is co-financed by the European Social Fund and the Youth European Initiative; grant number PEJ-2018-TL/BMD-11080Editor's Version
https://doi.org/10.1111/cts.12866Subjects
SARS‐CoV‐2; COVID-19; drugs; pharmacogenetic biomarkers; MedicinaRights
© 2020 The AuthorsAbstract
In December 2019, the severe acute respiratory syndrome virus-2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off-label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely
Files in this item
Google Scholar:Zubiaur, Pablo
-
Koller, Dora
-
Saiz-Rodríguez, Miriam
-
Navares-Gómez, Marcos
-
Abad Santos, Francisco
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.